IDEXX Laboratories (IDXX) Osake Kurssi
IDEXX Laboratories Kurssi
Viimeisten 19 vuoden aikana IDEXX Laboratoriesn liikevaihto kasvoi 9,7 % vuodessa ja ylsi 4,30 Mrd. USD:een. Osakekohtainen tulos on kasvanut 16,2 % vuodessa viimeisten 19 vuoden aikana. IDEXX Laboratoriesn nettomarginaali 24,6 % on noussut verrattuna 23,2 %:iin muutama vuosi sitten. IDEXX Laboratoriesn 12 kuukauden konsensustavoitehinta on 665,00 USD, noin yli kurssia 25,7 %. 22 analyytikosta 14 suosittaa ostoa — kokonaiskonsensus on Osta.
IDEXX Laboratories osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
IDEXX Laboratories liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset IDEXX Laboratories -osakkeesta
IDEXX Laboratories Inc is a global leader in veterinary diagnostics and software solutions. Their business model revolves around providing innovative products and services to veterinary practices, livestock producers, and pharmaceutical companies. IDEXX offers a wide range of diagnostic tests, instruments, and consumables that aid in the detection and prevention of diseases in animals. Their software solutions enable veterinary practices to streamline their operations, manage patient data, and enhance overall patient care. With a strong focus on research and development, IDEXX continuously strives to introduce advanced technologies and improve the quality of veterinary care worldwide.
IDEXX Laboratories Inc is primarily active in the animal health industry.
The main competitors of IDEXX Laboratories Inc in the market are Zoetis Inc, Heska Corporation, and Abaxis, Inc.
IDEXX Laboratories Inc. is a leading global company in veterinary diagnostics and software solutions. Founded in 1983, IDEXX has built a strong reputation for offering innovative products and services to support the animal healthcare industry. The company's mission is to improve the health and well-being of pets, livestock, and wildlife. IDEXX provides a wide range of diagnostic tests, instruments, and digital imaging systems that help veterinarians accurately diagnose diseases and ensure the best possible care for animals. With its headquarters in Maine, USA, IDEXX has an extensive network of customers worldwide. As a pioneer in animal diagnostics, IDEXX continues to drive advancements in veterinary medicine and enhance animal healthcare globally.
IDEXX Laboratories Inc, a renowned leader in veterinary diagnostics and software, has achieved numerous significant milestones over the years. The company pioneered the first veterinary reference laboratory, revolutionizing the field of animal health diagnostics. IDEXX also developed innovative technologies such as the SNAP test, providing immediate results for veterinarians. Furthermore, the company introduced groundbreaking products like the IDEXX ProCyte Dx Hematology Analyzer, enhancing the accuracy and efficiency of pet healthcare. With a commitment to continuous innovation, IDEXX Laboratories Inc has consistently redefined the standards in veterinary medicine, offering exceptional diagnostic solutions for veterinarians globally.
IDEXX Laboratories Inc is primarily present in various countries and regions worldwide. As a leading veterinary diagnostics and software provider, IDEXX operates in over 175 countries. Its operations span across North America, including the United States and Canada, as well as Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global presence, IDEXX consistently delivers innovative solutions and services to veterinary practices, animal healthcare professionals, and laboratories around the globe.
IDEXX Laboratories Inc represents strong values and a clear corporate philosophy. The company's values are centered around innovation, integrity, and collaboration. IDEXX is committed to continuously developing innovative diagnostic solutions to improve the health and well-being of animals worldwide. They uphold the highest standards of integrity in their business practices, ensuring transparency and trust with their customers and partners. Additionally, IDEXX promotes a culture of collaboration, fostering a diverse and inclusive environment that encourages teamwork and supports the growth and success of its employees. Through these values and corporate philosophy, IDEXX Laboratories Inc exemplifies its dedication to advancing animal healthcare globally.
Analyytikot asettavat tällä hetkellä IDEXX Laboratories-osakkeelle keskimääräisen tavoitehinnan 665,00 USD (mediaani: 665,00 USD), mikä merkitsee +25,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 22 analyytikkoarvioon.
22 analyytikkoa arvioi tällä hetkellä IDEXX Laboratories-osaketta: 14 suosittaa ostoa, 8 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat IDEXX Laboratories-yhtiöltä 4,72 Mrd. USD liikevaihtoa ja 14,82 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla IDEXX Laboratories-osake noteerataan hintaan 471,69 EUR (529,01 USD).
IDEXX Laboratories-osake (IDXX) on listattuna 9 pörssissä, muun muassa: NASDAQ (IDXX), London (0J8P.L), SIX (Zürich) (IX1.SW), XETRA (IX1.DE), Frankfurt (IX1.F), München (IX1.MU), Düsseldorf (IX1.DU), Wien (IDXX.VI).
IDEXX Laboratories Inc is a leading company in the field of animal health diagnostics and biotechnology. The company's business model is to offer innovative solutions to veterinarians, pet owners, and animal caretakers to improve the health and well-being of animals. IDEXX is divided into three main divisions: diagnostics and software, water testing, and animal genetics. Each division offers specialized products and services to meet the individual needs and requirements of customers. The diagnostics and software division of IDEXX offers a wide range of tests and instruments for the diagnosis of diseases in animals. The products range from simple blood tests to complex pathological examinations. IDEXX Labs specializes in tests for dogs, cats, and horses, offering a wide range of diagnostic options for these animals. The company also works closely with veterinarians and veterinary clinics to provide a wide range of diagnostic and laboratory services. In the water testing division, the company develops solutions for the detection of contaminants in drinking water and bottled water. This area of the business is focused on companies and government agencies that monitor the condition of water and want to ensure that it is safe for consumption. The animal genetics division of IDEXX offers breeding programs and tests for animals. The foundation of this division's work is DNA sequencing, which allows for the identification of genetic factors that can impact the health and behavior of animals. The animal genetics department works with veterinarians and pet owners to provide customer-oriented services that contribute to the improvement of animal health and breed. IDEXX is committed to providing its customers with innovative and advanced solutions. The company continuously invests in research and development to bring new products to the market and improve its existing offerings. IDEXX's business model is based on creating value by helping veterinarians and animal caretakers improve the health, well-being, and quality of life of animals. IDEXX also aims to integrate its products and services into the online market. To achieve this, the company develops various software solutions to ensure better portability and convenient connections to its services for customers. IDEXX is already involved in telemedicine, offering pet owners the opportunity to speak with veterinarians online and receive diagnoses. Overall, IDEXX's business model is focused on providing a comprehensive platform for animal health and biotechnology. Through its divisions in diagnostics, water testing, and animal genetics, the company has developed a wide range of products and solutions aimed at improving the health and well-being of animals and providing customers with high value.
odotettu liikevaihto IDEXX Laboratories on 4,72 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto IDEXX Laboratories on 1,20 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
IDEXX Laboratories:n hinta-voitto-suhde (P/E) on tällä hetkellä 35,69. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan IDEXX Laboratories-osakkeen arvostusta.
IDEXX Laboratories:n hinta-myynti-suhde (P/S) on tällä hetkellä 9,04. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii IDEXX Laboratories-osakkeen arvostuskennuslukuna.
IDEXX Laboratories:n Eulpool-laatuscore on 8/10.
IDEXX Laboratories:n ISIN on US45168D1046. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
IDEXX Laboratories:n WKN on 888210. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
IDEXX Laboratories:n ticker on IDXX. Tämä pörssinoteeraus käytetään IDEXX Laboratories-osakkeiden kauppaan pörssissä.
IDEXX Laboratories osake
IDEXX Laboratories vertaisryhmä
IDEXX Laboratories Ticker
IDEXX Laboratories FIGI
Kaikki tunnusluvut ja syvällinen analyysi IDEXX Laboratories:sta
Meidän osakeanalyysimme IDEXX Laboratories-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut IDEXX Laboratories:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: